Don’t miss this webinar tomorrow morning at 9:30 am EDT on Clinical trials for thymic tumors, moderated by Dr. Chul Kim. The webinar is free. Sign up here: itmig.org/event/clinical…
ITMIG Society Gilead Sciences #TETs #thymsm #ADCs #lcsm IASLC ASCO

In this episode of #OncLiveOnAir , experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Meeting. Stephen V Liu, MD Sumanta K. Pal, MD, FASCO Dr. Shubham Pant Vincent Rajkumar #ASCO2024 onclive.com/view/oncology-…

The ongoing development of Nuvalent’s zidesamtinib (NVL-520) is an important step forward for our ROS-1 #lungcancer & #cancer community. Here Dr Stephen V Liu, MD highlights the great promise & limited low grade toxicities.

onclive.com/view/dr-liu-on…

#lcsm ROS1ders UK The ROS1ders, Inc.

Looking forward to hearing more about these studies.
'Dr Stephen V Liu, MD Previews ASCO 2024 Lung Cancer Data'
onclive.com/view/dr-liu-pr… via @onclive

In this virtual tumor board episode of #LungCancerConsidered , host Stephen V Liu, MD leads a discussion about the management of metastatic PD-L1 low #NSCLC . W/guests Apar Kishor Ganti, from University of Nebraska Medical Center, & Dr. Sze Wai Chan, from the Sandton Oncology Centre. Listen Now: bit.ly/PDL1NSCLC24 #LCSM

Pre-application (LOI) submission due in one week for some of the FY24 CDMRP Department of Defense (DOD) Lung Cancer Research Program (LCRP) grants including the Concept Awards (preliminary data not required). First deadlines May 28th - info below!

cdmrp.health.mil/funding/lcrp

Report of real-world 5-year survival with 1L pembrolizumab in PD-L1 high NSCLC Clinical Lung Cancer. With median f/u 60.5m, median OS 19.2m, 5y OS rate 25.1%. Also noted 33% received subsequent therapy. Great real world collaboration with Dr. Vamsi Velcheti, MD MBA.

clinical-lung-cancer.com/article/S1525-…

Description of #ROS1 NSCLC in China (2018-2022) Lung Cancer Journal. ROS1 fusions (most common partner CD74) seen in 1.8% of cases (n=550/31225). Brain as site of progression in 27.6% of 1L and 39.2% of 2L. Median OS was 46m.
lungcancerjournal.info/article/S0169-…

The VA is studying how to expand lung cancer screening eligibility criteria through the multi-site MAS-EXPAND study led by Jennifer Lewis, MD MPH. It honors Pierre MASsion whose scientific spirit is captured in the study design. #ATS2024 news.vumc.org/2024/05/07/stu…

Looking forward to discussing Targeted Therapy in NSCLC at the UPMC Hillman Cancer Center Pittsburgh Annual Oncology Symposium on Friday August 23, 2024. Great lung sessions with Drs. Liza Villaruz, Mark Socinski, Tim Burns, and Sudhamshi Toom. Hope to see you there!

Lots of great work at the #WCLC24 planning meeting - it’s going to be a great conference to mark the IASLC 50th anniversary. Got a chance to explore San Diego a bit and had over half of my meals Tacos El Gordo #adobada

What goes into creating the #WCLC24 meeting program? A lot of work, many tacos, a lot of fun with colleagues and escaping from a tricky escape room!

IASLC WCLC24 Meeting Planning well underway. Appreciate all the busy folks who volunteer their time to make sure our 50th anniversary meeting will be our best yet!

Electronic nose tech uses exhaled volatile organic compounds and is being studied as a way to detect early stage lung cancers. Report of E-nose performance in pts with suspected stage I NSCLC JTO & JTO CRR shows promise. Can this complement CT screening?

jto.org/article/S1556-…

Dr. Marina Garassino with a concise and balanced editorial NEJM on CheckMate 77T and the perioperative immunotherapy approach for resectable NSCLC. Impressive results, but who benefits from the adjuvant portion specifically?

nejm.org/doi/full/10.10…